Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Other Events
Item 8.01 Other Events
On March 15, 2017, the Company issued a press release related to
the foregoing. The press release is attached hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith.
| Exhibit No. | Description | |
| 99.1 | Press Release |
About Immune Therapeutics, Inc. (OTCMKTS:IMUN)
Immune Therapeutics, Inc. is a biotechnology company. The Company is involved in the manufacturing, distribution and marketing of therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy. The Company’s products and immunotherapy technologies are designed to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. Its technology platform is built on various immunotherapies, such as Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Its technology offers treatment for a range of cancers. The Company’s clinical programs involve immunotherapy with Methionine-Enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which stimulates the immune system even in patients with advanced cancer. Immune Therapeutics, Inc. (OTCMKTS:IMUN) Recent Trading Information
Immune Therapeutics, Inc. (OTCMKTS:IMUN) closed its last trading session 00.0000 at 0.0400 with 1,704,087 shares trading hands.
